Peptide Synthesis Market: Global Industry Analysis and Forecast (2023-2029)

Peptide Synthesis Market was valued at US$ 562.68 Mn. in 2022. Global Peptide Synthesis Market size is expected to grow at a CAGR of 8 % through the forecast period.
Peptide Synthesis Market Overview:
Peptides are highly effective and selective signaling molecules that bind to particular cell surface receptors, such as ion channels or G protein-coupled receptors (GPCRs), where they cause intracellular reactions. Peptides are a good starting point for the creation of new therapies due to their excellent pharmacological profile and intrinsic characteristics. They are known to have outstanding safety, tolerability, and effectiveness characteristics in humans as a result of their specificity. Peptide therapeutics have lower processing complexity than protein-based biopharmaceuticals, which translates to lower production costs that are more similar to those of small molecules.To know about the Research Methodology :- Request Free Sample Report
Peptide Synthesis Market Dynamics:
In addition to the conventional peptide design, a number of new peptide technologies have emerged, representing growth opportunities for market players and the potential for further development of the peptide synthesis market. Among these are peptides with many functions and the ability to penetrate cells, peptide drug conjugates, and inventions based on novel administration methods.

Over the past ten years, peptides have been used for a wider range of purposes, including therapeutic peptide science and biotechnology. The market for peptide synthesis is the greatest benefit to a rise in the use of peptides for commercial reasons. For instance, Lupron, a peptide-based medication made by AbbVie that is used to treat illnesses including prostate cancer and others, had all sales of more than USD 755 million in 2020.

Important pharmaceutical, biotechnology, and peptide synthesis market participants have increased their R&d expenditure in response to the COVID-19 epidemic. Peptide synthesis has gained attention due to the increased demand for vaccinations and peptide-based medicines. The peptide-based strategy marks a turning point because peptides have proven to have distinctive characteristics of selectivity and specificity toward particular targets.

A peptide-based vaccination candidate called CoVac-1 is made up of SARS-CoV-2 T-cell epitopes derived from several viral proteins, along with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, with the goal of inducing strong SARS-CoV-2 T-cell immunity to fight off COVID-19. These developments have increased the need for materials and machinery for the manufacture of peptides.

Market Drive- Increasing use of peptide in the pharmaceutical sector

Peptides are extremely potent and targeted pharmacological ingredients. They are used in a wide variety of therapeutic areas because of the diversity of their biological actions. Due to their broad chemical space, high biological activity, high specificity, the relative simplicity of synthesis, ready availability, and low toxicity, peptides are increasingly being considered as potential active medicinal components.

Peptides bring in billions of dollars in three important therapeutic areas: oncology, diabetes, and obesity. The need for peptides is also rising for the treatment of renal failure, uncommon disorders, and cardiovascular and neurological illnesses. There are currently more than 100 peptide-based medications available. With almost 700 peptide medicines and therapeutic peptides now undergoing preclinical development, this figure is forecast to significantly increase.

Market Opportunity- Development of Personalized medicine

The concept of individualized therapy with the best response and largest safety margin to ensure improved patient care has sparked interest in personalized treatment. Proteomic analysis is an attractive and effective method for identifying the molecular profiles of distinct tissues, whether they are healthy or afflicted. The next significant advancement in customized medicine is personalized proteomics or proteomic profiling, which sheds new light on disease patho mechanisms.

As part of the EU-funded ElectroMed project, researchers suggested creating a user-friendly platform to program electrochemically guided peptide synthesis based on a microfluidic multiplexing system that is managed by software in order to increase the use of proteomics in personalized medicine.

Then, label-free sensors based on nanomaterials will be used to identify and quantify the ligand-receptor complexes. The technology will make it possible to apply proteomics for personalized treatment by enabling the automated injection of the various reagents required for the ligand synthesis for the personalized and controlled synthesis of peptides.

Growing investments in personalized medicine can be primarily due to the increased prevalence of diseases like cancer and cardiovascular disease (CVD) and the growing demand for reducing treatments with few adverse effects. Personalized medicine has the potential to raise healthcare quality while also cutting costs. Players in the peptide synthesis market will have growth potential as a result of such advancements in the area of customized medicine.

Market Challenges- Issue associated with the route of administration of peptide drug

Due to insufficient absorption from the gastrointestinal tract, the bulk of therapeutic peptides is supplied parenterally. The use of regular injections during long-term treatment has serious disadvantages, and peptide medicines are typically advised for chronic illnesses. The oral route of medication administration offers benefits including self-administration with a high degree of patient acceptability and compliance in contrast to this difficult and sometimes dangerous mode of drug delivery. Pre-systemic enzymatic breakdown and inadequate penetration of the intestinal mucosa are the main causes of the limited oral bioavailability of peptide drugs.

Additionally, the molecular weight, lipophilicity, and charged functional groups of these medicines are often high, which hinders absorption. These properties cause the majority of orally given peptides to have low bioavailability and brief half-lives. The problem of absorption is solved by intravenous or subcutaneous delivery of these therapeutics, but other factors, such as systemic proteases, rapid metabolism, opsonization, conformational changes, dissociation of subunit proteins, non-covalent complexation with blood products, and destruction of labile side-groups, limit the bioavailability of peptide and protein therapeutics.

Peptide-based medications are within the category of biologics, both small and large molecules. Peptides have created a number of regulatory issues due to their position on the threshold between usual tiny chemicals and large proteins. The majority of these medications are produced chemically.

Although diverse peptide medications have a similar production method, they all have quite different action mechanisms. Therefore, it is a difficult challenge to create a uniform set of regulatory rules that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various special modes of action. There are no official regulatory agency guidelines for creating this class of treatments.

Additionally, there is a conflict on the regulatory approval of peptide-based medicines between the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). The FDA's Center for Drug Evaluation and Research (CDER) is responsible for peptide drug evaluation, however, the European Medicines Agency (EMA) prefers a centralized process to the mutual recognition system (the marketing of peptide-based drugs is allowed throughout the European Union under the centralized procedure).

Therapeutic peptides are finding it difficult to obtain permits due to the intermittent nature of the laws, which in turn is limiting their potential uses. This is regarded as a significant barrier to the market for peptide synthesis growth.
Peptide Synthesis Market Segment Analysis:
Based on Product,

The product name, equipment, reagents & consumables, and others are used to segment the market for peptide synthesis into three categories. The four sub-segments of peptide synthesis equipment are further examined, including protein synthesizers, lyophilizers, chromatography equipment, and others. This market segment has experienced the quickest development in the world due to intensive research aimed at the production of innovative peptide synthesis equipment.

MIT researchers developed new machinery that made peptide synthesis faster than it was possible with previously available machinery. In order to produce vast amounts of personalized peptides in a smaller duration of time, researchers at MIT have developed an automated system that can join amino acids in about 37 seconds.

Reagents and consumables, on the other hand, have produced the largest revenue of all the products used in peptide synthesis; this is because peptide synthesis techniques frequently use them. In the upcoming years, it is also expected that recent advancements in peptide coupling reagents will accelerate market growth.



Based on the Technology, The market is divided into three categories based on technology: hybrid technology, liquid phase peptide synthesis (LPPS), and solid-phase peptide synthesis (SPPS). Throughout the forecast period, liquid-phase peptide synthesis has dominated the market, while solid-phase peptide synthesis has shown the highest increase between 2022 and 2029.

The expenses involved with peptide synthesis have been significantly decreased due to advancements and the incorporation of automation in both liquid and solid-phase synthesis. This is forecast to accelerate the adoption of peptide synthesis around the world, increasing the amount of revenue generated country over the course of the forecast period. SPPS is a good method for developing API processes and GMP manufacturing processes since it can produce lengthy peptide sequences (more than 10 amino acids) at a low cost in smaller numbers. However, when using SPPS, the costs of purification have a tendency to increase the price of manufacturing at any desired level of output.

Based on the Application,The peptide synthesis market is divided into medicines, diagnosis, and research categories based on the applications. Revenue from the therapeutics segment covers a range of conditions, including cancer, metabolic, cardiovascular, respiratory, gastrointestinal (GI) disorders, infectious illnesses, pain, dermatological, CNS, and renal.

The market for peptide synthesis applications has been dominated by the therapeutics sector since 2022, and this trend is forecast to continue over the coming years. However, from 2022 to 2029, the diagnosis category is forecast to grow at the quickest rate. Due to the widespread use of synthetic peptides in the treatment of cancer, this market has become a significant source of revenue for the therapeutics sector.

Additionally, the segment for metabolic disorders is forecast to boost at the quickest rate over the course of the forecast period, and this increase can be due to the pipeline's strength and the abundance of peptide candidates for the treatment of type II diabetes. It is expected that recently identified peptides important for metabolic regulation may provide helpful information for developing efficient treatment strategies.

Based on the End-Use, As per end-use, the peptide synthesis market is divided into three groups: pharmaceutical and biotechnology firms; contract development and manufacturing firms (CROs/CMOs); and academic and research institutions. A key factor in the dominance of pharmaceutical and biotechnology businesses' end-use sector in the market is the industry's robust rise in peptide therapies. While the CRO and CMO segments experienced the most growth between 2022 and 2029.
Regional Insights:
North America held the biggest market share for peptide synthesis in 2022, accounting for 38.6% of total market revenue. Europe and the Asia Pacific region came in second and third, respectively, with shares of 30.8 % and 27 %. The high prevalence of chronic diseases, rising investments in the development of structure-based drug designs, growing research in the fields of genomics and proteomics, and rising focus on the creation of personalized therapeutics are all factors that contribute to North America's significant market share in the world. In 2022, the US accounted for the largest share of the North American market. The significant US market share is primarily explained by the country's growing life science research activities as well as the rising incidence of chronic illnesses like cancer.

The objective of the report is to present a comprehensive analysis of the global Peptide Synthesis Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The reports also help in understanding the Peptide Synthesis Market dynamic, structure by analyzing the market segments and projecting the Peptide Synthesis Market size. Clear representation of competitive analysis of key players by Vehicle type, price, financial position, product portfolio, growth strategies, and regional presence in the Peptide Synthesis Market make the report investor’s guide.
Peptide Synthesis Market Scope: Inquire before buying



Global Peptide Synthesis Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2018 to 2022
Market Size in 2022:
US$ 562.68 Mn.


Forecast Period 2023 to 2029 CAGR:
8%
Market Size in 2029:
US$ 964.33 Mn.


 Segments Covered:
by Product
Equipment
Reagents & Consumables
Others


by Application
Therapeutics
Diagnosis
Research


by End-User
Pharmaceutical & Biotechnology Companies
Contract Development & Manufacturing Organization
Academic & Research Institutes


by Technology
Solid Phase Peptide Synthesis
Liquid Phase Peptide Synthesis
Hybrid Technology



by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Peptide Synthesis Market Key Players
1. Bachem Holdings (Switzerland)
2. Thermo Fisher Scientific (US)
3. Merck KGgA (Germany)
4. GenScript Biotech Corporation (China)
5. Kaneka Corporation (Japan)
6. Biotage AG (Sweden)
7. Syngen International Ltd (India)
8. Mesa Laboratories (US)
9. CEM Corporation (US)
10.ProteoGenix (France)
11.Bio-Synthesis (US)
12.Purolite (US)
13.ChemPep (US)
14.AmbioPharm (US)

Frequently Asked Questions:

1] What segments are covered in the Global Peptide Synthesis Market report?
Ans. The segments covered in the Peptide Synthesis Market report are based on Product, Technology, Application and End User.

2] Which region is expected to hold the highest share in the Global Peptide Synthesis Market?
Ans. The North America region is expected to hold the highest share in the Peptide Synthesis Market.

3] What is the market size of the Global Peptide Synthesis Market by 2029?
Ans. The market size of the Peptide Synthesis Market by 2029 is expected to reach US$ 964.33 Mn.

4] What is the forecast period for the Global Peptide Synthesis Market?
Ans. The forecast period for the Peptide Synthesis Market is 2023-2029.

5] What was the market size of the Global Peptide Synthesis Market in 2022?
Ans. The market size of the Peptide Synthesis Market in 2022 was valued at US$ 562.68 Mn.